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Allergic asthma often coexists with different pathological
conditions, called multimorbidities, that are mostly of allergic
nature and share a common underlying inﬂammatory
pathophysiological mechanism. Multimorbidities of allergic
asthma may inﬂuence asthma control, its severity, and patients’
response to treatment, and contribute to the overall
socioeconomic burden of the disease. Immunoglobulin E (IgE) is
known to play a central role in the pathogenesis of various allergic
diseases, including asthma. Thus, IgE-mediated immunologic
pathways present an attractive target for intervention in asthma
and multimorbidities. In this review, we discuss the most
frequently reported IgE-mediated multimorbidities in allergic
asthma, including allergic rhinitis, rhinoconjunctivitis, atopic
dermatitis, vernal keratoconjunctivitis, chronic rhinosinusitis
with nasal polyps, food allergies, and allergic bronchopulmonary
aspergillosis. Omalizumab is a recombinant humanized
monoclonal antibody against IgE and has been in use to treat
allergic asthma for more than a decade. We comprehensively
review the clinical evidence for omalizumab in the treatment of
the aforementioned multimorbidities in allergic
asthma. ! 2018 The Authors. Published by Elsevier Inc. on
behalf of the American Academy of Allergy, Asthma &
Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(J Allergy Clin Immunol Pract 2019;7:1418-29)
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Allergic bronchopulmonary aspergillosis
Allergic asthma is a chronic disease of the airways involving a
complex interplay between multiple inﬂammatory cells and
mediators.1 The disease is characterized by reversible airway
obstruction and airway hyperresponsiveness on exposure to aer-
oallergens; it is deﬁned by immunoglobulin E (IgE) sensitization,
which is clinically diagnosed based on the presence of a clinically
apparent allergic reaction and an IgE response to speciﬁc
aeroallergens.2
Although allergic conditions, including asthma, are frequently
managed as single entities, their coexistence/co-occurrence as
multimorbidities is a common phenomenon. The term multi-
morbidity is used to indicate the clustering and co-occurrence of
diseases with a common pathological mechanism in an individ-
ual, where the primary disease is not clear.3 Patients with allergic
asthma very frequently also present with allergic rhinitis (AR) or
rhinoconjunctivitis,4 whereas patients with chronic rhinosinusitis
with nasal polyps (CRSwNP) often have asthma as a multi-
morbidity. In children, atopic dermatitis (AD) is commonly
associated with asthma.5 Along with the aforementioned condi-
tions, allergic bronchopulmonary aspergillosis (ABPA) and food
allergies represent other multimorbidities.6-11 Multimorbidities
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Abbreviations used
ABPA- Allergic bronchopulmonary aspergillosis
AD- Atopic dermatitis
AR- Allergic rhinitis
CRS- Chronic rhinosinusitis
CRSsNP- Chronic rhinosinusitis without nasal polyps
CRSwNP- Chronic rhinosinusitis with nasal polyps
CSU- Chronic spontaneous urticaria
MeDALL-Mechanisms of the Development of ALLergy program
OIT- Oral immunotherapy
SE- Staphylococcus aureus enterotoxin
Spl- Staphylococcus aureusederived serine proteaseelike
protein
Th2 cells- T-helper-2 cells
VKC- Vernal keratoconjunctivitis
have been shown to contribute to poor asthma control and
subsequent overtreatment of patients.12 Furthermore, multi-
morbidities are associated with increased health care costs in
patients with severe asthma.8,13 In severe allergic asthma, coex-
isting upper airway pathological conditions present a complex
multimorbidity but often share a common pathophysiological
mechanism (eg, type 2 immune response) that displays consid-
erable heterogeneity. It is known that inﬂammation plays an
important role in the initiation and progression of multi-
morbidities of asthma.14
IgE has been convincingly linked to the pathophysiology of
allergic asthma and other allergic conditions.15 IgE-mediated
allergic diseases involve multiple genetic and environmental
components that interact to determine disease expression and lead
to heterogeneous and frequently coexisting phenotypes.16 Com-
plex allergic diseases such as asthma, rhinitis, conjunctivitis, and
food allergy may be associated with allergen-speciﬁc IgE and
nonallergic mechanisms that can coexist in the same patient
(termed allergic comorbidity cluster or multimorbidity) and share
causal mechanisms.16,17 An FP7 European Union project (No.
264357), the Mechanisms of the Development of ALLergy pro-
gram (MeDALL), was initiated to identify novel mechanisms of
allergy initiation during early childhood through to young adult-
hood. Approximately 38% of allergic multimorbidities were
associated with IgE sensitization in the MeDALL study; further-
more, rather than being the sole factor for multimorbidities, IgE
sensitization was suggested to be a component of a broader
phenotypical presentation of patients characterized by poly-
sensitization and multimorbidity, which was associated with the
frequency, persistence, and severity of allergic symptoms.16,18
In this review, we provide an overview of the major pathological
conditions with an IgE component presenting as multimorbidities
with allergic asthma, and we discuss the available evidence for anti-
IgE therapy with omalizumab as a viable option in the manage-
ment of patients with IgE-mediated multimorbidities.
ROLE OF IgE IN ALLERGIC PATHOPHYSIOLOGY
The mechanism of allergic asthma and the key role of IgE in
its pathophysiology have been extensively studied.19,20 Research
has demonstrated that IgE plays a fundamental role in the trig-
gering, development, and chronicity of the inﬂammatory re-
sponses within the disease.19 IgE constitutes only a small fraction
of the total antibodies in human serum and has the shortest half-
life in serum (approximately 2 days).21 IgE binds to high-afﬁnity
FcεRI receptors expressed on the surface of mast cells and ba-
sophils and to low-afﬁnity FcεRII receptors expressed on B cells
and other hematopoietic cells, which signiﬁcantly enhances the
half-life of IgE.22,23 IgE activity is enhanced by speciﬁc cell-
surface receptor interaction, and the expression is tightly regu-
lated in the absence of allergic disease.1,21-23
On initial allergen exposure, antigen-presenting dendritic cells
sensitize naïve T cells to the allergen and direct their develop-
ment into T-helper-2 (Th2) cells. This induces production of
inﬂammatory cytokines IL-4 and IL-13 that increase FcεRII
expression and trigger B cells to produce allergen-speciﬁc
IgE.21,22 During their class-switching to IgE-secreting plasma
cells, B cells also express membrane-bound IgE, which assists in
antigen processing and signal transduction. Secreted IgE binds to
the FcεRI on mast cells and basophils and sensitizes them to the
allergen. Repeated allergen exposure leads to cross-linking of
membrane-bound IgE in mast cells and basophils, inducing
cellular degranulation and the release of histamine, tryptase,
cysteine-leukotrienes, and platelet-activating factors. These cy-
tokines affect the early allergic response manifested in edema,
vasodilation, and bronchoconstriction.18,23 The events induced
in the early response lead to the production and release of cy-
tokines and chemokines such as IL-3, IL-4, IL-5, IL-13, CC
chemokine ligand-5, and granulocyte-macrophage colony-stim-
ulating factor, which recruit inﬂammatory cells such as neutro-
phils, eosinophils, basophils, T cells, and macrophages to the site
of inﬂammation.18,23,24 This process is known as the late allergic
response, characterized by mucus hypersecretion, airway
inﬂammation, hyperresponsiveness, and airway remodeling
(Figure 1). Along with the stated role of IgE-induced inﬂam-
matory mediators, it should be noted that the activation of
allergen-speciﬁc memory Th2 cells by antigen-presenting cells via
IgE-facilitated allergen presentation is also key for the clinical
manifestation of late allergic response.25
COMPILATION OF LITERATURE ON ALLERGIC
MULTIMORBIDITIES AND CLINICAL EVALUATION
OF OMALIZUMAB
To compile relevant literature on multimorbidities to be
included in this review, we conducted a literature search using
the PubMed database. The search using terms “multimorbidity
OR multimorbidities” and “asthma” yielded a total of 106
publications. Additional searches were carried out using the
names of individual conditions, for example, “allergic rhinitis”
AND “asthma.” The literature review was carried out for pub-
lication years 1999 to 2018, restricting the articles to humans
and English language publications. Potentially eligible publica-
tions were manually screened and reviewed, and nonrelevant
publications were excluded based on predetermined criteria such
as excluding editorials, opinion pieces, articles that did not have
the full text available, and articles without authors.
IgE-MEDIATED MULTIMORBIDITIES AND THE
EFFECT OF OMALIZUMAB
More than 70% of symptomatic patients with allergy (having at
least 1 positive skin prick test or at least 1 speciﬁc IgE> 0.35 kU/L)
may be sensitized and clinically allergic to either 1 (mono-
sensitization) or more allergens (polysensitization).15 de Jong
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et al26 proposed to use the term “paucisensitization” to describe 2
to 4 sensitizations and “polysensitization” to describe 5 or more
sensitizations. Polysensitization can be categorized into: (1) cross-
reactivity/cross-sensitization, which is the same IgE binding to
several different allergens with common structural features; and (2)
cosensitization, which is the simultaneous presence of different
IgEs that bind to allergens that may not necessarily have common
structural features.27 Important clinical and immunological dif-
ferences exist between patients who are mono- and polysensitized,
which indicates that polysensitization is the expression of a distinct
disease in both children and adults. Persistence of allergic diseases
over time is associated with multimorbidity and/or allergic poly-
sensitization; moreover, polysensitization was shown to be higher
in patients with multimorbidity in comparison with those with a
single allergic disease.15
Some studies in allergic asthma have shown that multi-
morbidities are independent predictors of key asthma out-
comes.28 Therefore, the choice of treatment in patients with
severe asthma should be optimized based on any existing mul-
timorbidities as these may deﬁne the asthma phenotype and
FIGURE 1. Immunological mechanisms in IgE-mediated allergic diseases. Th2 cell, T-helper-2 cell.
FIGURE 2. Multimorbidities associated with severe allergic
asthma. ABPA, Allergic bronchopulmonary aspergillosis;
CRSwNP, chronic rhinosinusitis with nasal polyps.
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consequently could affect asthma treatment outcomes.29 Indeed,
the American Thoracic Society/European Respiratory Society
guidelines now recognize the identiﬁcation of multimorbidities
as an essential part of treating severe asthma.30 Therefore, the
management of multimorbidities is central to the systematic
approach to overall asthma control.28-31 The multimorbidities in
asthma discussed in this review are AR/rhinoconjunctivitis,
vernal keratoconjunctivitis (VKC), AD, CRSwNP, food allergies,
and ABPA (Figure 2).
Allergic rhinitis and rhinoconjunctivitis
AR is a symptomatic disorder of thenasalmucusmembranes after
allergen exposure, characterized by IgE-mediated inﬂammation of
these membranes.32 Compelling evidence exists for the overlap
between AR and asthma.33,34 AR and asthma are characterized by a
similar inﬂammatory response as the upper and lower airways have a
similar cellular structure of ciliated, pseudostratiﬁed columnar
epithelium with goblet cells; nevertheless, it should be noted that
differences do exist in the extent of tissue remodeling between the
TABLE I. Efficacy of omalizumab in patients with allergic rhinitis/rhinoconjunctivitis
Study Design No. of patients Primary (or coprimary) endpoint Primary outcome
Adelroth et al44 A randomized, double-blind, placebo-
controlled, parallel-group study
251 Average daily nasal symptom
severity score (sneezing, itching,
runny, and stuffy nose) from
diary data collected over the
double-blind treatment period
Signiﬁcant between-treatment
differences (P < .001) in favor of
omalizumab were observed in
average daily nasal symptom
severity scores
Casale et al45 A randomized, double-blind,
placebo-controlled, multicenter,
dose-ranging study
536 The average daily nasal symptom
severity score
Average nasal symptom severity and
duration scores over the entire
pollen season were consistently and
signiﬁcantly lower in the
omalizumab 300 mg group vs the
placebo group (P ¼ .002). During
the severe pollen season, average
nasal symptom severity scores were
also signiﬁcantly lower in the 300
mg (P ¼ .001) and 150 mg (P ¼
.01) omalizumab groups than in the
placebo group
Chervinsky et al46 A randomized, double-blind,
phase 3 study
289 Mean daily nasal severity score
(as determined from patient
daily diary cards) during
16 wk of treatment
During 16 wk of treatment, the mean
daily nasal severity score was
signiﬁcantly lower in omalizumab-
treated patients compared with
placebo (P < .001)
Vignola et al47 A multicenter, randomized,
double-blind, parallel-group,
placebo-controlled study
405 Incidence of asthma exacerbations
during the 28-wk treatment
period and the proportion of
patients with improvement in
both asthma and rhinitis
QoL scores
Fewer patients treated with
omalizumab experienced asthma
exacerbations (20.6%) than
placebo-treated patients (30.1%;
P ¼ .02). A clinically signiﬁcant
("1.0 point) improvement in both
asthma QoL questionnaire and
rhinitis QoL questionnaire was seen
in 57.7% of omalizumab patients
compared with 40.6% of placebo
patients (P < .001)
Masieri et al48 A longitudinal study 11 General clinical conditions and
intensity of individual symptoms
(nasal obstruction, rhinorrhea,
itching, sneezing, tearing) using
the visual analog scale (VAS;
1 ¼ no symptoms, to
10 ¼ worst possible symptoms)
VAS scores for general
symptomatology (P ¼ .0125) and
symptoms including nasal
obstruction (P ¼ .005), rhinorrhea
(P ¼ .007), itching (P ¼ .041), and
sneezing (P < .003) were
signiﬁcantly reduced with
omalizumab compared with
baseline
Kopp et al49 A randomized, double-blind,
placebo-controlled, multicenter
study
130 Superiority of depigmented speciﬁc
immunotherapy (SIT) in
combination with omalizumab
compared with depigmented SIT
monotherapy for daily symptom
load averaged over the pollen
season of the core study
Combination therapy of SIT with
omalizumab reduced the symptom
load by 39% (P ¼ .0464) over SIT
monotherapy. This difference was
mainly due to reduced symptom
severity (P ¼ .0044)
QoL, Quality of life.
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nose (in AR) and bronchi (in asthma).34,35 Several epidemiologic
studies have provided strong evidence for the association of the
development of asthma with a previous history of either seasonal or
perennial AR.36,37 Large worldwide studies such as The Interna-
tional Study of Asthma and Allergies in Childhood epidemiological
research program conducted between 2002 and 2003 showed that
the prevalence of asthma, AR, allergic rhinoconjunctivitis, and other
allergic diseases had risen when compared with 5 years before the
study.38 Previous epidemiological studies have reported that up to
40% of patients with AR also developed asthma and up to 80% of
patients with asthma reported having AR.33,39,40 In a recent study,
the coexistence of asthma andARwas found tobe themost common
allergic multimorbidity,41 supporting the “one airway, one disease”
hypothesis and common epidemiologic, pathologic, andphysiologic
characteristics, and a common therapeutic approach for both rhinitis
and asthma.42 The association of rhinoconjunctivitis and asthma
TABLE III. Efficacy of omalizumab in patients with chronic rhinosinusitis
Study Design No. of patients Primary (or coprimary) endpoint Primary outcome
Gevaert et al71 A randomized, double-blind,
placebo-controlled study
24 The difference in total nasal
endoscopic polyp scores
compared with baseline after
16 wk of treatment
There was a signiﬁcant decrease in
total nasal endoscopic polyp
scores after 16 wk in the
omalizumab-treated group
(#2.67, P ¼ .001) compared
with baseline
Vennera Mdel et al72 Case studies 19 The size of NP scored in both nasal
cavities using nasal endoscopy.
Scored as 0 (no polyp), 1 (polyps
restricted to the middle meatus),
2 (polyps in the middle meatus
but not reaching the upper edge
of the inferior turbinate), 3
(polyps between the upper and
lower edges of the inferior
turbinate), and 4 (large polyps
reaching the ﬂoor of the nasal
fossa), with a bilateral total score
ranging from 0 to 8
NP size was signiﬁcantly reduced at
the end of follow-up vs baseline
(P ¼ .035). No patient needed
additional surgery during
omalizumab treatment
Penn and Mikula73 A retrospective study 8 Effect of omalizumab on recurrence
of nasal polyps after endoscopic
sinus surgery using sinus
computed tomography and nasal
endoscopic examination
The nasal polyp scores signiﬁcantly
improved in the omalizumab-
treated patients than in the
preoperative group
NP, Nasal polyps.
TABLE II. Efficacy of omalizumab in patients with asthma and vernal keratoconjunctivitis
Study Design No. of patients Primary (or coprimary) endpoint Primary outcome
Sánchez et al53 Case study 1 Clinical effect of omalizumab in a
patient with severe vernal
keratoconjunctivitis coexistent
with asthma
After 6 wk of omalizumab therapy,
the patient presented clinically
important improvement in ocular
symptoms
de klerk et al54 Case study 1 Clinical effect of omalizumab in a
patient with severe vernal
keratoconjunctivitis coexistent
with asthma
Signs and symptoms of vernal
keratoconjunctivitis resolved
completely with monthly
subcutaneous omalizumab
treatment
Doan et al55 Retrospective review
of case studies
4 Clinical effect of omalizumab in
patients with severe vernal
keratoconjunctivitis coexistent
with asthma
Three patients responded to
omalizumab treatment, with a
decrease in global symptoms
(median symptom rating
decreasing from 89 to 29 on a
100-mm visual analog scale),
frequency and in duration of the
inﬂammatory ﬂares, and also a
decreased need for topical steroid
Occasi et al56 Case study 1 Clinical effect of omalizumab in a
patient with vernal
keratoconjunctivitis coexistent
with uncontrolled asthma
After 3 mo of treatment with
omalizumab, asthma control was
reached a complete resolution of
vernal keratoconjunctivitis
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symptomswas shown tobe frequent and associatedwithmore severe
asthma symptoms in patients with concomitant AR.43
Clinical evaluation of omalizumab. Both randomized-
controlled and observational-type clinical studies have demon-
strated the effectiveness and safety of omalizumab in patients with
AR. The study populations included patients with a history of
seasonal or perennial AR as well as those with seasonal AR and
concomitant severe asthma. In these studies, omalizumab provided
improvement in symptoms, as indicated by signiﬁcantly lower
symptom scores on treatment, reduction in concomitant and
rescue medication use, improved quality of life, decreased IgE
levels, and reduction in asthma exacerbations. The ﬁndings from a
few key relevant clinical studies are presented in Table I.
Vernal keratoconjunctivitis
VKC is a chronic relapsing allergic eye disease with immediate
and delayed hypersensitivity reactions (both IgE and non-IgE
mediated) that can result in signiﬁcant visual loss.50 Conven-
tional therapy for allergic conjunctivitis is generally not adequate
for VKC;51 in a large retrospective study, almost 85% of patients
with VKC required treatment with topical corticosteroids at
some point during follow-up.52
Clinical evaluation of omalizumab. A few reports have
shown promising results of omalizumab in the treatment in
both adults and children with VKC coexisting with asthma,
without the excessive adverse effects associated with topical
corticosteroid therapy. It should be noted that these ﬁndings
are mostly from case studies and thus are from a very small
patient population. Therefore, controlled studies in a larger
number of patients are required to determine the treatment
regimen with omalizumab in patients with VKC. We have
presented the ﬁndings from a few key relevant case studies in
Table II.
Chronic rhinosinusitis
Chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) or
without (CRSsNP) involves long-term inﬂammation of the
paranasal sinus mucosa for a minimum of 12 weeks; speciﬁcally
in CRSwNP, patients may suffer with the condition for de-
cades.57,58 Patients with CRSwNP are especially prone to
develop asthma and show an incidence of asthma of 20% to 70%
dependent on the degree of type 2 inﬂammation in the polyp
mucosa.59 CRSwNP is prevalent in 4% of the asthmatic patients
and around 15% of nonatopic asthmatic patients; however, these
ﬁgures may be higher when patients are thoroughly investigated,
including nasal endoscopy.17 It is important to note that the
conventional phenotyping of CRS into CRSwNP and CRSsNP
might not adequately reﬂect the pathophysiological variety
among patients with CRS; in this regard, distinct inﬂammatory
endotypes have been identiﬁed within patients with CRS, which
largely correlated with phenotypes and further differentiated the
phenotypes.59 The GA2LEN study showed that there is a very
strong association of CRS with asthma; almost 40% of patients
with asthma suffered from comorbid CRS.60 Higher levels of
sputum and serum eosinophils, and exhaled nitric oxide levels, in
patients with CRS suggest that it is closely related to lower airway
inﬂammation in severe asthma.61 CRSwNP is associated with
local immunoglobulin hyperproduction and the presence of IgE
antibodies against Staphylococcus aureus enterotoxins (SEs), also
called staphylococcal superantigens.62 This is in line with the
evidence that both CRSwNP and asthma show increased nasal
S. aureus colonization.63-65 S. aureusederived serine
proteaseelike protein (Spl) D and other proteases secreted by
S. aureus have recently been identiﬁed as inducers of allergic
TABLE IV. Efficacy of omalizumab in patients with atopic dermatitis
Study Design No. of patients Primary (or coprimary) endpoint Primary outcome
Iyengar et al78 Randomized, placebo-controlled
study
8 Levels of thymic stromal
lymphopoietin (TSLP), thymus
and activation-regulated
chemokine (TARC), OX40
ligand (OX40L), and other
cytokines involved in atopic
dermatitis (AD) measured by
using cytometric bead arrays;
Scoring Atopic Dermatitis
(SCORAD) scores
All patients receiving omalizumab
had substantially decreased levels
of TSLP, OX40L, TARC
(involved in T-helper-2
polarization) and IL-9 compared
with placebo. Patients who
received omalizumab showed
SCORAD score reductions of
approximately 20% to 50%
Heil et al79 An explorative single center,
randomized, placebo-controlled,
double-blind mechanistic study
20 Effect of omalizumab on
immunological disease parameters
assessed throughout the study:
ﬂow cytometry, immunohistology,
and the measurement of serum IgE
levels
Omalizumab: (1) reduced free serum
IgE, (2) lowered surface IgE and
FcεRI expression on different
peripheral blood mononuclear
cells, (3) reduced the saturation of
FcεRI with IgE, (4) increased the
number of free FcεRI, and (5)
lowered the number of IgEþ, but
not of FcεRIþ cells in skin
Sheinkopf et al82 Prospective analysis of
treatment efﬁcacy
21 AD severity at 0, 1, 3, 6, and
9 mo via an Investigator
Global Assessment index
based on a modiﬁed
SCORAD index
All patients showed clinical and
statistically signiﬁcant
improvement of their atopic
dermatitis from month 0 to months
1, 3, 6, and 9 on treatment with
omalizumab
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asthma.66 The Spls act as allergens and superallergens, shifting
the immune reaction further into type 2 inﬂammation.54,66 The
presence of both the enterotoxins and the Spls has been
demonstrated in the upper airway mucosa using proteomics.67
Studies have shown the presence of polyclonal-speciﬁc IgE,
including IgE to SEs, a high total IgE level, and a high prevalence
of asthma in patients with NP;68 it has been postulated that
mucosal polyclonal IgE contribute to persistent inﬂammation by
continuously activating mast cells in patients with NP.69 IgE to
SEs can be measured in serum, and SE-induced IgE levels have
been shown to be a risk factor for asthma severity.65,70 In
addition, increased levels of total IgE were predictive of asthma
comorbidity in patients with CRSwNP.66
Clinical evaluation of omalizumab. Omalizumab was
found to be effective in reducing the severity of nasal polyps in
TABLE V. Efficacy of omalizumab in patients with food allergies
Study Design No. of patients Primary (or coprimary) endpoint Primary outcome
Andorf et al92 A blinded, phase 2, randomized,
controlled study
48 Proportion of patients who passed
double-blind, placebo-controlled
food challenges to at least 2 of
their offending foods at week 36
At week 36, a signiﬁcantly greater
proportion of the omalizumab-
treated (30 [83%] of 36) vs placebo
(4 [33%] of 12) participants passed
double-blind, placebo-controlled
food challenges to 2 or more of
their offending foods (odds ratio:
10.0, 95% CI 1$8-58$3, P ¼
.0044)
Raﬁ et al96 A prospective pilot study 22 Symptoms and severity of allergic
reaction before and after
omalizumab treatment for 1-y
duration
All patients displayed signiﬁcant
improvement as shown by a
decrease/lack of symptoms on re-
exposure to sensitized foods.
Clinical improvement by the sixth
dosage of omalizumab (150-300
mg every 2-4 wk) was noted by
history and physical examination
Sampson et al97 A phase 2, randomized,
double-blind, parallel-group,
placebo-controlled study
14 Tolerability to peanut in allergic
patients
Omalizumab increased the
tolerability to peanut: 4 (44.4%)
omalizumab-treated subjects vs 1
(20%) placebo-treated subject
could tolerate >1000 mg peanut
ﬂour during an oral food challenge
after 24 wk of treatment with study
drug (P ¼ .324)
Wood et al99 A double-blind,
placebo-controlled study
57 Sustained unresponsiveness, deﬁned
as the absence of dose-limiting
symptoms in both month 28 and
month 32 oral food challenges, ie,
sustained unresponsiveness
measured after 8 wk off of milk
oral immunotherapy in patients
treated with omalizumab vs
placebo
At month 28, a total of 24 (88.9%)
omalizumab-treated patients and
20 (71.4%) placebo-treated
patients passed the
“desensitization” oral food
challenge (P ¼ .18). At month 32,
sustained unresponsiveness was
observed in 48.1% in the
omalizumab group and 35.7% in
the placebo group (P ¼ .42)
Schneider et al100 Desensitization study 13 Rate of desensitization to peanut
allergy
After pretreatment with omalizumab,
all patients tolerated the initial 11
desensitization doses given on the
ﬁrst day, including the maximum
dose of 500 mg peanut ﬂour,
requiring minimal or no rescue
therapy
MacGinnitie et al101 Desensitization study 37 Rate of desensitization to peanut
allergy
The median peanut dose tolerated on
the initial desensitization day was
250 mg for omalizumab-treated
patients vs 22.5 mg for placebo-
treated patients. Twenty-three
patients receiving omalizumab vs 1
patient receiving placebo passed
the 4000 mg food challenge
CI, Conﬁdence interval.
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patients with coexisting severe asthma. We have presented the
outcomes of a few key relevant clinical studies in Table III. It
should be noted that the evidence presented here is mainly from
noncontrolled and case studies, which included a low number of
patients; in this regard, larger controlled clinical trials would be
needed to determine the generalized efﬁcacy and regimen of
omalizumab in these patients. Currently, the effectiveness of
omalizumab in nasal polyps (with or without concurrent asthma)
is being explored in 2 ongoing phase 3 randomized clinical trials
(Clinicaltrials.gov: NCT03280550, NCT03280537).
Atopic dermatitis
AD, AR, and asthma are said to form the triad of atopic
diseases. AD is one of the most common allergic skin disorders
found in children. The prevalence of AD is up to 24% in
developed countries, and has risen in recent years together with
an increased prevalence of asthma, representing a major burden
on health care cost.74,75 AD is frequently associated with elevated
serum IgE levels in individuals with a history of allergies and
respiratory symptoms such as AR and allergic asthma.17 The
epidermal and dermal dendritic cells both express high-afﬁnity
FcεRI receptors on their cell surface. It has been estimated that
approximately one-third of young patients with AD develop
asthma.76 Moreover, a signiﬁcant relationship has been demon-
strated between the severity of AD and bronchial asthma, and the
duration of the skin lesions.77
Clinical evaluation of omalizumab. Overall, omalizumab
was not markedly effective in treating AD in patients with
asthma78-82 (Table IV). Moreover, recommendation for its use in
clinical practice for patients with AD awaits evidence from larger
randomized controlled trials.80 The Atopic Dermatitis Anti-IgE
Paediatric Trial is one such randomized study that will assess
whether omalizumab improves AD compared with placebo in
patients with coexisting asthma.81
Food allergies
Food allergies are immune-mediated adverse reactions to
various foods that may involve IgE-mediated immediate hyper-
sensitivity reactions, delayed noneIgE-mediated reactions, or
contributions from both IgE-mediated and noneIgE-mediated
immune pathways.83 Most commonly encountered food aller-
gens include milk, eggs, tree nuts, peanuts, soy, wheat, ﬁsh, and
shellﬁsh. IgE-mediated food allergy can affect all ages, impacts
quality of life, and can lead to very severe—even fatal—reactions
as well as cross-reactive IgE responses to inhalant allergens.84
Overall, the prevalence of food allergies ranges from less than
0.2% to more than 10%; the prevalence is inﬂuenced by factors
including age (eg, egg and milk are major allergens in children
but disappear later in life) and geographical location.85 An EU-
funded integrated project (EuroPrevall) was conducted to pro-
vide a framework for identiﬁcation of risk factors and manage-
ment of food allergies by examining the complex interactions
between food intake and metabolism, immune system, genetic
background, and socioeconomic factors.86 In the INCO Euro-
Prevall study, probable food allergy was deﬁned as self-reporting
of adverse symptoms after the consumption of food and a speciﬁc
IgE level of "0.35 kUA/L to the same food.87 Children suffering
from coexisting food allergies and asthma were at increased risk
of severe anaphylaxis, which can be fatal, particularly if their
asthma was uncontrolled.88 Although it is known that allergic
reactions to food can trigger lower respiratory symptoms and
asthma, food allergy generally does not present with chronic or
isolated respiratory symptoms.88
Clinical evaluation of omalizumab. Oral immunotherapy
(OIT) is more effective than other routes in the treatment of
food allergies, but safety has been a major limitation due to the
risk of adverse reactions.89 To improve the safety proﬁle of OIT
and maintain or increase its efﬁcacy, adjuvant therapy with
omalizumab has been explored in several trials in severe peanut
allergy, milk allergy, egg allergy, and multiple food allergy, with
signiﬁcant clinical improvement in both adults and children.90-92
Recent evidence has suggested that the concomitant use of
omalizumab with OIT can improve OIT protocols and out-
comes in patients with food allergies.93-96 This effect correlated
with the effect of omalizumab on basophil reactivity, which may
play a vital role in the early events of allergic response to
food.94-96 In addition, several studies have assessed the effect of
anti-IgE monotherapy in patients with food allergy. In a phase 2
study, omalizumab was shown to signiﬁcantly increase the
TABLE VI. Efficacy of omalizumab in patients with allergic bronchopulmonary aspergillosis
Study Design No. of patients Primary (or coprimary) endpoint Primary outcome
Aydın et al107 A retrospective
chart review
14 Lung function, asthma control test
score, mean oral corticosteroid
usage, asthma exacerbations,
hospitalization
Treatment with omalizumab resulted
in: (1) signiﬁcant increase in FEV1
from baseline (P ¼ .02); (2)
increase in mean asthma control
test score at all time points
compared with the basal score
(P ¼ .001); (3) signiﬁcantly
decreased mean oral corticosteroid
dosage (P ¼ .001); and (4) zero
exacerbation and hospitalization
rate at the ﬁnal assessment. Eleven
of the patients (78.6%) responded
perfectly to omalizumab
Voskamp et al108 A randomized, double-blind,
placebo-controlled,
cross-over study
13 Number of exacerbations Rate of exacerbations decreased
signiﬁcantly in the active treatment
phase compared with the placebo
phase (2 vs 12 events, P ¼ .048)
FEV1, Forced expiratory volume in 1 s.
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tolerability of allergic patients to peanut compared with placebo
on oral food challenge, although this study was stopped early.97
A placebo-controlled study that evaluated the efﬁcacy of anti-IgE
monotherapy (with talizumab) in patients with peanut allergy
showed that the threshold of sensitivity to peanut on oral food
challenge was signiﬁcantly increased with this therapy.98 Table V
describes the details of key clinical studies that evaluated the
efﬁcacy of omalizumab in patients with food allergy.
Allergic bronchopulmonary aspergillosis
ABPA is an allergic pulmonary disorder caused by hypersen-
sitivity to the fungus Aspergillus species (most commonly
Aspergillus fumigatus). ABPA is also sometimes classiﬁed as a
distinct endotype of asthma based on its speciﬁc pathophysio-
logical mechanisms. Globally, it has been reported that over 4.8
million patients with asthma have ABPA; however, the exact
prevalence of this disease is still unknown.102 According to the
International Society for Human and Animal Mycology working
group, the prevalence of aspergillus sensitization in patients with
asthma ranged from 5.5% to 38.5%, and the prevalence of
ABPA varied between 2.5% and 22.3%, with a pooled preva-
lence of 8.4% in asthma.103 The fungal antigens from
A. fumigatus cause a type I (IgE-mediated) reaction that is
responsible for presentation of ABPA. Type III (IgG-mediated
immune complex) and type IV (cell-mediated) responses have
also been implicated, but tissue invasion does not occur.
Therefore, the total IgE levels are generally high in ABPA.104,105
Clinical evaluation of omalizumab. A systematic review
of 102 cases from 30 publications showed that treatment
with omalizumab reduced serum free IgE levels in patients
with ABPA, especially in those with a baseline IgE level of
>1000 IU/mL, and also reduced asthma exacerbations, thus
showing potential beneﬁts in severe ABPA.106 In addition,
retrospective analysis of case studies and randomized studies have
demonstrated that omalizumab improved asthma symptoms and
lung function in patients with asthma and ABPA107,108
(Table VI). However, larger randomized, double-blind,
placebo-controlled trials are required to establish the effective-
ness of omalizumab in this patient population.106
SUMMARY AND CONCLUSIONS
The important role of IgE in mediating allergic reactions is
well established and best corroborated by the clinical beneﬁts of
the anti-IgE monoclonal antibody omalizumab in allergic dis-
eases.109,110 Similar to coexisting conditions in other diseases,
IgE-mediated multimorbidities in patients with allergic asthma
contribute to the lack of disease control and impose a consid-
erable burden on patients, caregivers, and health care systems.111
Because IgE is involved in pathologies distinct from or over-
lapping with those of asthma, anti-IgE therapy is approved for
chronic spontaneous urticaria (CSU) and is currently being
assessed in conditions such as AR, CRSwNP, AD, and food al-
lergies.109 Indeed, targeting IgE has proved to be a successful
approach to allergic diseases that have poor responses to con-
ventional treatments. Although the approved indications for
omalizumab are currently limited to allergic asthma and CSU, its
potential in the treatment of other allergic multimorbidities is
becoming increasingly apparent.111 Evidence suggests that the
treatment of allergic asthma with omalizumab not only results in
improvements in asthma symptoms but also frequently improves
outcomes of any coexisting conditions.112,113 A retrospective,
observational study that assessed the efﬁcacy of omalizumab in
patients with asthma and other concomitant allergic diseases such
as rhinosinusitis, AD, and ABPA showed improvement in
symptoms of these allergic diseases, suggesting that omalizumab
has a role in allergic disease beyond its current use.114 Even
beyond diseases with an atopy component, omalizumab reduced
bronchial mucosal IgEþ mast cells, downregulated FcεRI
expression, and improved lung function despite withdrawal of
conventional therapy in nonatopic asthmatics.115,116
In spite of common components in their pathogenesis, allergic
diseases are still viewed as independent conditions. Although the
nature of the association among different allergic diseases is still
under investigation, it is acknowledged that they tend to cluster
and patients may present with concomitant or consecutive dis-
eases, that is, allergic multimorbidities. Studies that will assess the
relationship between coexisting diseases in groups of patients
with different allergic sensitizations will provide important in-
sights into the impact of multimorbidities. Furthermore, despite
the growing evidence for the application of anti-IgE therapy in
IgE-mediated multimorbidities of allergic asthma, larger and
well-designed clinical studies may further conﬁrm the efﬁcacy
and safety of the use of omalizumab. It should be noted that
because patients with allergic multimorbidities may exhibit
higher levels of IgE than those indicated in the dosing table for
asthma, the dosages of anti-IgE treatments would need to be
adjusted to achieve optimal efﬁcacy in treating these conditions.
Future research may provide a better understanding of the
interplay between multimorbidities and allergic asthma, thus
helping to identify targeted treatments and improve clinical
outcomes in these coexisting allergic diseases.
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